3-异丙基[1,2,4]三唑并[4,3-a]吡啶-6-甲醛 | 459448-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 3-异丙基[1,2,4]三唑并[4,3-a]吡啶-6-甲醛
• 英文名称: 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde
• 英文别名: 3-ISOPROPYL-[1,2,4]TRIAZOLO(4,3-A)-6-PYRIDINECARBOXALDEHYDE；3-isopropyl[1,2,4]triazolo(4,3-a)-6-pyridinecarboxaldehyde；3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine-6-carbaldehyde；3-isopropyl-[1,2,4]triazolo(4,3-A)pyridinecarboxaldehyde；3-isopropyl[1,2,4]triazolo[4,3-a]pyridine-6-carbaldehyde；3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridine-6-carbaldehyde
• CAS: 459448-04-5
• 化学式: C₁₀H₁₁N₃O
• mdl: MFCD08272051
• 分子量: 189.217
• InChiKey: NSYUIEIIQDSMID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-异丙基[1,2,4]三唑并[4,3-a]吡啶-6-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 (3-propan-2-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)methanol
  参考文献：
  名称：

  WO2006/18735

  摘要：

  公开号：
• 作为产物：
  描述：

  N,N-二甲基甲酰胺 在 异丙基氯化镁 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.17h， 以97%的产率得到3-异丙基[1,2,4]三唑并[4,3-a]吡啶-6-甲醛
  参考文献：
  名称：

  [EN] TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION
  [FR] NOUVEAUX COMPOSES DE TRIAZOLOPYRIDINE POUR LE TRAITEMENT D'INFLAMMATION

  摘要：

  公开号：

  WO2006018727A3

文献信息

• [EN] TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] TRIAZOLO-PYRIDINES UTILISEES COMME COMPOSES ANTI-INFLAMMATOIRES
  申请人：PFIZER PROD INC

  公开号：WO2004072072A1

  公开（公告）日：2004-08-26

  The present invention relates to novel triazolo-pyridines of the formula (I) wherein X is >CH2, >NH, sulfur, >S=O, >S02 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent; R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; R2 is selected from the group consisting of hydrogen, (Cl-C6)alkyl and other suitable 10 substituents; s is an integer from 0-4; R3 is R4, R5-(NR6)-, R5-S-, R5-(S=O)-, R5-(S02)-, R5-S02-NR6-, R5-(NR6)-S02-, R5-O-,R5-(C=O)-, R5-(NR6)-(C=O)-, R5-(C=O)-NR6-, R5-O-(C=O)-, R5-(C=O)-O-, R5-CR7=CR8- or R5-C=-C-; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 15 AMU; R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及具有以下式(I)的新型三唑吡啶，其中X为>CH2，>NH，硫，>S=O，>SO2或氧；其中所述的> 和>NH可以选择性地被适当的取代基取代；R1选自氢，(C1-C6)烷基和其他适当的取代基组成的群；R2选自氢，(Cl-C6)烷基和其他适当的取代基组成的群；s为0-4的整数；R3为R4，R5-(NR6)-，R5-S-，R5-(S=O)-，R5-(SO2)-，R5-SO2-NR6-，R5-(NR6)-SO2-，R5-O-，R5-(C=O)-，R5-(NR6)-(C=O)-，R5-(C=O)-NR6-，R5-O-(C=O)-，R5-(C=O)-O-，R5-CR7=CR8-或R5-C=-C-；使得R3的分子量小于500 AMU，最好小于250 AMU；R4，R5和R6分别选自氢，(C1-C6)烷基和其他适当的取代基组成的群；或其药学上可接受的盐；用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中具有用途。
• Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
  申请人：Pfizer Inc

  公开号：US20040092547A1

  公开（公告）日：2004-05-13

  The present invention relates to novel alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新型烷基-［4-(二氟苯基)-噁唑-5-基］-三唑-吡啶类化合物，其中包括用于制备它们的中间体、含有它们的制药组合物以及它们在医学上的应用。本发明的化合物是MAP激酶的有效抑制剂，特别是p38激酶。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、脑卒中或心肌梗塞的再灌注或缺血、自身免疫性疾病和其他疾病中有用。
• Novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
  申请人：Pfizer Inc

  公开号：US20040143119A1

  公开（公告）日：2004-07-22

  The present invention relates to novel crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine to pharmaceutical compositions containing such crystal forms and to methods of treatment. 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is a potent inhibitor of MAP kinases, preferably p38 kinase (MAPK14/CSBP/RK kinase). 3-Isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-a]pyridine is useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶的新结晶形式，以及含有这种晶体形式的制药组合物和治疗方法。3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶是MAP激酶的有效抑制剂，优选为p38激酶（MAPK14/CSBP/RK激酶）。3-异丙基-6-[4-(2,5-二氟苯基)-噁唑-5-基]-[1,2,4]三唑-[4,3-a]吡啶在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病方面有用。
• Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
  申请人：Pfizer Inc

  公开号：US20040077682A1

  公开（公告）日：2004-04-22

  The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及一种新的烷基-[4-(三氟苯基)-噁唑-5-基]-三唑并吡啶化合物，其中间体和制备方法，含有它们的制药组合物以及它们的医药用途。本发明化合物是MAP激酶的有效抑制剂，优选p38激酶。它们在炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病的再灌注或缺血、自身免疫性疾病和其他疾病的治疗中有用。
• [EN] DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] COMPOSES ANTI-INFLAMMATOIRES A BASE DE DI- ET TRIFLUORO-TRIAZOLO-PYRIDINES
  申请人：PFIZER PROD INC

  公开号：WO2004020440A1

  公开（公告）日：2004-03-11

  The present invention relates to novel triazolo-pyridines of the formula (I) wherein R1 is fluoro; s is an integer from two to three; R2 is (C3-C6)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (Cl-C4)alkyl, hydroxy, (Cl-C6)alkoxy and (C1-C6)alkyl-(C=O)-0-; or R2 is (Cl-C6)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy and (C1-C6)alkyl-(C=O)-0-; with the proviso that said compound of formula (I) cannot be 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or 6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及式(I)的新型三唑吡啶，其中R1为氟；s为2至3的整数；R2为（C3-C6）环烷基，可选地取代为从卤素，（Cl-C4）烷基，羟基，（Cl-C6）烷氧基和（C1-C6）烷基-（C=O）-0-中独立选择的一种或两种基团；或R2为（Cl-C6）烷基，可选地取代为从卤素，（C1-C6）烷基，羟基，（C1-C6）烷氧基和（C1-C6）烷基-（C=O）-0-中独立选择的一种或两种基团；但是，具有式(I)的化合物不能为6-[4-(2,4-二氟苯基)-噁唑-5-基]-3-异丙基-[1,2,4]三唑并[4,3-a]吡啶；或6-[4-(3,4-二氟苯基)-噁唑-5-基]-3-异丙基-[1,2,4]三唑并[4,3-a]吡啶；本发明还涉及其制备中间体、含有它们的制药组合物以及它们的医药用途。本发明的化合物是MAP激酶，特别是p38激酶的有效抑制剂。它们在炎症，骨关节炎，类风湿性关节炎，癌症，中风或心脏病的再灌注或缺血，自身免疫性疾病和其他疾病的治疗中有用。